$1.47 Billion is the total value of RTW INVESTMENTS, LP's 50 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LIVN | Sell | LivaNova PLC | $42,317,000 | +4.4% | 435,136 | -1.8% | 2.89% | -23.4% |
| SRPT | Sell | Sarepta Therapeutics Inc | $40,310,000 | +0.9% | 338,199 | -7.6% | 2.75% | -26.0% |
| AGEN | Sell | Agenus Inc | $29,353,000 | +21.7% | 9,883,213 | -2.5% | 2.00% | -10.7% |
| ARWR | Sell | Arrowhead Pharmaceuticals In | $28,043,000 | -57.5% | 1,528,213 | -71.3% | 1.91% | -68.9% |
| RGNX | Sell | Regenxbio Inc | $25,857,000 | -41.3% | 451,182 | -57.0% | 1.76% | -57.0% |
| PRNB | Sell | Principia Biopharma Inc | $15,502,000 | +9.5% | 455,948 | -18.0% | 1.06% | -19.7% |
| QURE | Sell | Uniqure NV | $9,190,000 | -31.0% | 154,058 | -66.6% | 0.63% | -49.4% |
| CDNA | Sell | CareDx Inc | $6,987,000 | -15.2% | 221,663 | -32.4% | 0.48% | -37.8% |
| STIM | Sell | Neuronetics Inc | $2,540,000 | -21.7% | 166,561 | -0.7% | 0.17% | -42.7% |
| VRAY | Sell | Viewray Inc | $1,177,000 | -85.8% | 159,247 | -88.3% | 0.08% | -89.6% |
| RMED | Exit | RA MED SYS INC | $0 | – | -61,281 | -100.0% | -0.04% | – |
| LIVN | Exit | LIVANOVA PLCput | $0 | – | -7,900 | -100.0% | -0.07% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS IN | $0 | – | -313,466 | -100.0% | -0.10% | – |
| ASMB | Exit | Assembly Biosciences Inc | $0 | – | -686,644 | -100.0% | -1.45% | – |
| SAGE | Exit | SAGE Therapeutics Inc | $0 | – | -165,990 | -100.0% | -1.48% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.